Abstract
Cancer Immunology Type 2 innate lymphoid cells (ILC2s) are known to help initiate and coordinate allergic and anthelmintic immunity. Recent studies have also pointed to the role that ILC2s play in the promotion and inhibition of various cancers. Jacquelot et al. show that in melanoma, ILC2s infiltrate tumors and control antitumor immunity. Tumor-infiltrating ILC2s produce the proinflammatory cytokine GM-CSF, which in turn enhances the recruitment, activation, and survival of anti-melanoma eosinophils. Notably, these ILC2s also express programmed cell death protein-1 (PD-1), which dampens their antitumor activity. When the authors combined anti–PD-1 immunotherapy with administration of the ILC2-activating cytokine interleukin-33 in a mouse model of melanoma, they saw better antitumor responses. ILC2 and eosinophil accumulation in tumors correlated with improved melanoma patient survival, suggesting that these cell populations have potential as cancer immunotherapy targets. Nat. Immunol. 22 , 851 (2021).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
